Vaccination Status and Effectiveness of COVID‐19 Vaccines in Patients with Prostate and Bladder Cancer

Considering the importance of understanding COVID-19 prevalence and vaccine effectiveness in individuals dealing with bladder or prostate cancer, as well as the plausible adverse repercussions of immunization, this study was undertaken to as- sess the prevalence and vaccination rates of COVID-19 in this group of patients. Furthermore, the investigation seeks to evaluate potential adverse effects and the efficacy of vaccines in patients diagnosed with prostate and bladder cancer. In this cross-sectional study conducted from 2020 to 2022, we systematically extracted clini- cal and demographic information, COVID-19 diagnoses, clinical symptoms, and par- aclinical data from the bladder and prostate cancer registry at our institution. Our analysis encompassed assessing the frequency of COVID-19 infections, vaccination rates, and the occurrence of adverse effects associated with vaccination within this specific cohort. Among the 249 enrolled patients, COVID-19 infection was confirmed in 19.4% of bladder cancer patients and 16.6% of prostate cancer patients. A substan- tial majority, 81% (202 patients), had received vaccination, with the Sinopharm vac- cine being the preferred choice for the majority (90%). The study’s outcomes reveal a vaccine efficacy of 82% in individuals with bladder cancer, while displaying a higher efficacy of 96% among patients with prostate cancer. This study provides evidence supporting the efficacy of the SARS-CoV-2 vaccine in reducing COVID-19-associated complications and mortality, as well as its high efficacy in patients with prostate and bladder cancer.